<SEC-DOCUMENT>0001493152-21-028346.txt : 20211115
<SEC-HEADER>0001493152-21-028346.hdr.sgml : 20211115
<ACCEPTANCE-DATETIME>20211115084641
ACCESSION NUMBER:		0001493152-21-028346
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211115
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211115
DATE AS OF CHANGE:		20211115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celsion CORP
		CENTRAL INDEX KEY:			0000749647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				521256615
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15911
		FILM NUMBER:		211406652

	BUSINESS ADDRESS:	
		STREET 1:		997 LENOX DRIVE
		STREET 2:		SUITE 100
		CITY:			LAWRENCEVILLE
		STATE:			NJ
		ZIP:			08648
		BUSINESS PHONE:		(609) 896-9100

	MAIL ADDRESS:	
		STREET 1:		997 LENOX DRIVE
		STREET 2:		SUITE 100
		CITY:			LAWRENCEVILLE
		STATE:			NJ
		ZIP:			08648

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CELSION CORP
		DATE OF NAME CHANGE:	19980515

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEUNG LABORATORIES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:CLSN="http://celsion.com/20211115">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_CLSN_celsion.com_20211115 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20211115_20211115 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0000749647 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityCentralIndexKey">0000749647</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="clsn-20211115.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-11-15to2021-11-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-15</xbrli:startDate>
        <xbrli:endDate>2021-11-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_903_edei--DocumentType_c20211115__20211115_znP26dBsVmYf"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date
of Report (Date of earliest event reported): <span id="xdx_90A_edei--DocumentPeriodEndDate_c20211115__20211115_zZLRRTKslBfg"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">November 15, 2021</ix:nonNumeric></span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span id="xdx_90D_edei--EntityRegistrantName_c20211115__20211115_zPhAGPJFe7A7"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityRegistrantName">CELSION
CORPORATION</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Exact
name of registrant as specified in its Charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20211115__20211115_zeHTjTfySgh2"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_900_edei--EntityFileNumber_c20211115__20211115_zILf90eweLVh"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityFileNumber">001-15911</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20211115__20211115_z0A4loc2n6zb"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityTaxIdentificationNumber">52-1256615</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(State
    or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Commission</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>File
    Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(IRS
    Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20211115__20211115_z4SXFvf8uyk6"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityAddressAddressLine1">997
    Lenox Drive</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressAddressLine2_c20211115__20211115_zOU1B5kx67Z4"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityAddressAddressLine2">Suite 100</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressCityOrTown_c20211115__20211115_zO1mbPq01DXh"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityAddressCityOrTown">Lawrenceville</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20211115__20211115_zSV8M8yxaD3k"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20211115__20211115_zS65PlRzqZG9"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityAddressPostalZipCode">08648-2311</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Address
    of principal executive offices)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Zip
    Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--CityAreaCode_c20211115__20211115_zoVD8i8l0rec"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:CityAreaCode">(609)</ix:nonNumeric></span>
<span id="xdx_90E_edei--LocalPhoneNumber_c20211115__20211115_zJXm7KwngY0k"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:LocalPhoneNumber">896-9100</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Registrant&#8217;s
telephone number, including area code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>N/A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Former
name or former address, if changed since last report.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--WrittenCommunications_c20211115__20211115_zv9cQCmzk0Nc"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--SolicitingMaterial_c20211115__20211115_zphH0yEpCPd7"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--PreCommencementTenderOffer_c20211115__20211115_zvnlvX6u2gsf"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20211115__20211115_zxq4yGtILlIk"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font: 10pt Times New Roman, Times, Serif">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><span style="font: 10pt Times New Roman, Times, Serif">Trading
    symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><span style="font: 10pt Times New Roman, Times, Serif">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--Security12bTitle_c20211115__20211115_zBnCcjgDKQhk"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:Security12bTitle">Common
    stock, par value $0.01 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--TradingSymbol_c20211115__20211115_zmm4eF0kCb5d"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:TradingSymbol">CLSN</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span><span id="xdx_904_edei--SecurityExchangeName_c20211115__20211115_zFYxfLMk6msf"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
growth company <span id="xdx_901_edei--EntityEmergingGrowthCompany_c20211115__20211115_z6gw4oXoK4i7"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
2.02 Results of Operations and Financial Condition.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
November 15, 2021, Celsion Corporation issued a press release reporting its financial results for the quarter ended September 30, 2021.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span>On
November 9, 2021, Celsion Corporation announced it would hold a conference call on November 15, 2021 to discuss its financial results
for the quarter ended September 30, 2021 and provide a business update. The conference call will also be broadcast live on the internet
at <span style="text-decoration: underline">http://www.celsion.com</span>.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
information in this report, including the exhibit hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections
11 and 12(a)(2) of the Securities Act of 1933, as amended. Such information shall not be incorporated by reference into any filing with
the Securities and Exchange Commission made by Celsion Corporation, whether made before or after the date hereof, regardless of any general
incorporation language in such filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. Please refer to the cautionary note in the press release regarding these
forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(d)
Exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.65in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>No.</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">99.1
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex99-1.htm">Press
    Release titled &#8220;Celsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update&#8221; issued
    by Celsion Corporation on November 15, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>CELSION
    CORPORATION</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Dated:
    November 15, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Jeffrey W. Church</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Jeffrey
    W. Church</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Executive
    Vice President and Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFTc0KgkAQfgLfYdhzWGt0yGNSEVmISHTdcool3ZHZzfKRestWJRo+GGa+PyEmYksbXSHDeZWnUGDdVMoh5HhDRnNFr0h2+xj8zvGurWNl3HD+jAl5D3rPIlxe/H9QttpiGYOUU49IgoziuYTsIIKeT8jcdInGaVWBMiVkTA1rdIq7MaFQbzJUd0PTCdlqMj4unI30B6KZjOBIrXoRPyykaSKCyTCB2DI9m77maR3VsK6w9l12tP4RfAHbJ0kU -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="logo_ex99-1.jpg" ALT="" STYLE="height: 60px; width: 150px"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Celsion
Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Balance
Sheet Supports Focus on Immuno-Oncology and Next-Generation Vaccine Initiative</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conference
Call Begins Today at 11:00 a.m. Eastern Time</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LAWRENCEVILLE,
N.J</B>. <B>(November 15, 2021) &ndash; Celsion Corporation (NASDAQ: CLSN)</B>, <FONT STYLE="background-color: white">a clinical-stage
drug-development company focused on DNA-based immunotherapy and next-generation vaccines, </FONT>today announced financial results for
the three and nine months ended September 30, 2021, and provided an update on clinical development programs with <FONT STYLE="background-color: white">GEN-1,
a DNA-based </FONT>interleukin-12 (IL-12) <FONT STYLE="background-color: white">immunotherapy </FONT>in Phase II clinical development
for the treatment of advanced-stage ovarian cancer (Stage III/IV)<FONT STYLE="background-color: white">, and ThermoDox</FONT><SUP>&reg;</SUP><FONT STYLE="background-color: white">,
a proprietary heat-activated liposomal encapsulation of doxorubicin under investigator-sponsored development for several cancer indications.
In addition, </FONT>Celsion <FONT STYLE="background-color: white">has two feasibility-stage platform technologies for the development
of novel nucleic acid-based immunotherapies and next-generation vaccines for infectious diseases.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;GEN-1
continues to show momentum as patient enrollment nears 70% with full enrollment targeted by the first half of 2022. We are encouraged
with surgical resection results at the 100 mg/m&sup2; dose cohort in the Phase II OVATION 2 Study. From the first 36 patients with interval
debulking surgery, 80% treated with GEN-1 at a dose of 100 mg/m&sup2; plus neoadjuvant chemotherapy (NACT) had a complete tumor resection
(R0), which indicates a microscopically margin-negative resection with no gross or microscopic tumor remaining in the tumor bed; this
compares with 56% of patients in the control arm having R0 resections. These results are reasonably consistent with those reported from
our earlier Phase I trials in advanced-stage ovarian cancer<FONT STYLE="background-color: white">,&rdquo; </FONT>said Michael H. Tardugno,
Celsion&rsquo;s chairman, president and chief executive officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&ldquo;At
the International Vaccines Congress in October, Celsion </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announced
results from preclinical <I>in vivo </I>studies showing production of antibodies and cytotoxic T-cell response specific to the spike
antigen of SARS-CoV-2 when immunizing BALB/c mice with our next-generation PLACCINE DNA vaccine<FONT STYLE="color: black">,&rdquo; added
Mr. Tardugno. &ldquo;Our goal over the next several quarters is to demonstrate the superiority of Celsion&rsquo;s multicistronic DNA
vaccine over current mRNA vaccines with respect to the quality of immune response (higher affinity of neutralizing antibodies, IgG titers
and T-cell response) against multiple SARS-CoV-2 variants, longer duration of immune response and a stable product at lower temperatures.&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GEN-1
Immunotherapy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interim
Data Reported on the OVATION 2 Study.</I></B> Interim clinical data from the first 36 patients who have undergone interval debulking
surgery are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20
    patients were treated with GEN-1 at a dose of 100 mg/m&sup2; plus NACT, with 16 out of 20 patients (80%) having R0 resections.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16
    patients were treated with NACT only, with 9 out of 16 patients (56%) having R0 resections.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    combining these results with the surgical resection rates observed in the Company&rsquo;s prior Phase Ib dose-escalation trial (the
    OVATION 1 Study), a population of patients with inclusion criteria identical to the OVATION 2 Study, the data reflect the strong
    dose-dependent efficacy of adding GEN-1 to NACT.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>%
    Patients with R0 Resections</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0,
    36, 47 mg/m&sup2; of GEN-1 plus NACT</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n=22</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT> %</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61,
    79, 100 mg/m&sup2; of GEN-1 plus NACT</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n=28</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</FONT> %</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for the 16 patients treated
    with NACT only were comparable, as expected, to the 20 patients treated with GEN-1 at a dose of 100 mg/m&sup2; plus NACT, with both
    groups demonstrating an approximate 80% ORR.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Publication
of OVATION 1 Study in the <I>Journal of Clinical Cancer Research</I>. </B>In July 2021, the Company announced the publication of data
from its Phase 1b OVATION 1 Study with GEN-1 in combination with NACT in patients with advanced ovarian cancer in <I>Clinical Cancer
Research, </I>a journal of the American Association for Cancer Research. The study, authored by Premel H. Thaker, M.D. <I>et al.</I>
and titled &ldquo;GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I
Dose-Escalation Study,&rdquo; is available here. Dr. Thaker, Professor of Gynecologic Oncology and Director of Gynecologic Oncology Clinical
Research at the Washington University School of Medicine in St. Louis, is the study chair for the OVATION program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
OVATION 1 Study enrolled 18 patients with newly diagnosed stage IIIC and IV epithelial ovarian cancer in a standard 3+3 dose-escalation
design testing four GEN-1 doses (36 mg/m<SUP>2</SUP>, 47 mg/m<SUP>2</SUP>, 61 mg/m<SUP>2</SUP> and 79 mg/m<SUP>2</SUP>) in combination
with NACT (carboplatin-paclitaxel). There were 15 patients evaluable for safety, and 14 underwent interval debulking and were evaluable
for RECIST.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously reported, there were no dose-limiting toxicities. As shown in the chart below, in the two highest doses of GEN-1 the objective
response rate was 100% and the R0 resection rate was 88%. Newly published data show the CRS, which was analyzed in this paper for the
first time, was 50% in the two highest doses of GEN-1, compared with 28% from a major publication evaluating CRS scoring.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><P STYLE="text-align: center; font: 16pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAB 4 &ndash; Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></B></FONT></P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
Responses: Tumor Response, Surgical Outcome, Pathological Response and Chemotherapy Response Score with NAC/GEN-1</B> E<B>scalating Doses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Radiographic
                                            Response</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
                                            (n)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cohort
    1 <BR>
36 mg/m<SUP>2</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cohort
    2 <BR>
47 mg/m<SUP>2</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cohort
    3 <BR>
61 mg/m<SUP>2</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cohort
    4 <BR>
79 mg/m<SUP>2</SUP></B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; font-weight: bold; text-align: left"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CR</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tumor Response</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PR</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SD</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Objective
    Response Rate</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67%</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">R0</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Surgical Outcome</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">R1</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">R2</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">R0 Resection
    Rate</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33%</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cPR</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pathological Response</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Micro</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Macro</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cPR/Micro
    Rate</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60%</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRS 3</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chemotherapy Response Score</B>&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRS 2</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRS 1</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRS 3 Rate</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17%</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Translational
Responses: IL-12 and IFN-&gamma; Levels, Response to Immune-Suppressive Agents; Ratio of CD8+ Cells to Immune Suppressive Agents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    dose-dependent increase in immunostimulatory cytokines IL-12 and its downstream cytokine IFN-&gamma; in ascitic fluid. The anticancer
    effects of these cytokines are widely recognized in human malignancies.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    proportion of myeloid dendritic cells in the peritoneal fluid trended higher (3.1-fold) accompanied by a similar 3.0-fold rise in
    CD8+ cells.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEN-1
    appeared to reduce four immunosuppressive signals (Foxp3, IDO1, PD-1 and PD-L1) within the tumor microenvironment, a trend not seen
    with NAC therapy alone.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEN-1
    appeared to stimulate the body&rsquo;s immune system through the production of CD4 and CD8 cells.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEN-1
    gene therapy was associated with an apparent increase in the cytotoxic state of T cells within the tumor microenvironment as indicated
    by the increases in the ratios of CD8+/CD4+ and CD8+/Treg cells. Indeed, higher CD8+/CD4+ T cell and CD8+/Treg ratios are considered
    prognostic for prolonged survival.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><P STYLE="text-align: center; font: 16pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAB 4 &ndash; Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></B></FONT></P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vaccine
Initiative</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Vaccine
Advisory Board Expanded</I></B><I>.</I> In July 2021, the Company </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announced
the addition of Dan H. Barouch, M.D., Ph.D. and Luke D. Handke, Ph.D. to its Vaccine Advisory Board (VAB). They joined Britt A. Glaunsinger,
Ph.D. and Xinzhen Yang, M.D., Ph.D. on the VAB, which was formed in February 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Barouch is the principal investigator at the Barouch Laboratory, Director of the Center for Virology and Vaccine Research at Beth Israel
Deaconess Medical Center and William Bosworth Castle Professor of Medicine at Harvard Medical School. In addition, he is a key participant
in the Bill &amp; Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery, the National Institutes of Health Martin Delaney
HIV-1 Cure Collaboratory and the Ragon Institute of MGH, MIT and Harvard. Dr. Barouch and his team were instrumental in developing the
vector, a variant of an adenovirus called Ad26, that was used to make single-dose vaccines for HIV, tuberculosis and Zika, and ultimately,
in conjunction with Johnson &amp; Johnson researchers, SARS-CoV-2. He has authored numerous peer-reviewed articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Handke is a highly skilled molecular biologist and microbiologist with a decade of pharmaceutical industry experience including nine
years with Pfizer&rsquo;s Vaccine Research and Early Development Unit. At Pfizer he served as molecular biology lead on an early phase
viral vaccine program and was the lead reviewer of data sources and literature citations for licensure application for the Trumenba<SUP>&reg;
</SUP>meningococcal group B vaccine in the U.S. and in Europe. He began his career in vaccine research at Wyeth. He is co-author and
co-inventor on various patent applications for a protein-based RSV vaccine and a SARS-CoV-2 detection assay and authored 10 peer-reviewed
publications including six as first author. Dr. Handke is currently a Senior Scientist at the University of Nebraska Medical Center in
Omaha. In addition to serving on the VAB, Dr. Handke will provide consulting services to Celsion in connection with its vaccine-development
program, which involves DNA-based vectors in combination with proprietary non-viral cellular delivery agents. He also will advise Celsion
as it advances this program into human clinical studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Results
from </I>In Vivo <I>Studies with PLACCINE DNA Vaccine Platform Indicate Immune Response Against SARS-Cov-2</I></B>. In September 2021,
the Company announced results from preclinical <I>in vivo </I>studies showing production of antibodies and cytotoxic T-cell response
specific to the spike antigen of SARS-CoV-2 when immunizing BALB/c mice with the Company&rsquo;s next-generation PLACCINE DNA vaccine
platform. Moreover, the antibodies to SARS-CoV-2 spike antigen prevented the infection of cultured cells in a viral neutralization assay.
The production of antibodies predicts the ability of PLACCINE to protect against SARS-CoV-2 exposure, and the elicitation of cytotoxic
T-cell response shows the vaccine&rsquo;s potential to eradicate cells infected with SARS-CoV-2. These findings demonstrate the potential
immunogenicity of Celsion&rsquo;s PLACCINE DNA vaccine, which is hypothesized to provide broad-spectrum protection and resistance against
variants by incorporating multiple viral antigens, to improve vaccine stability at storage temperatures of 4<SUP>o</SUP>C and above,
and to facilitate cheaper and easier manufacturing. Celsion reported these data at the International Vaccines Conference in October 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Agreement
with Hainan Poly Pharm to Manufacture Celsion&rsquo;s DNA-based Vaccine. </I></B>In September 2021, the Company announced an amendment
to its existing contract manufacturing agreement with Hainan Poly Pharm Co. Ltd., a generics manufacturer dedicated to providing therapeutic-value
products and services to patients and customers around the world, to include development work for the Company&rsquo;s investigational
DNA-based COVID-19 vaccine. Under the terms of the amended agreement, Poly Pharm will manufacture clinical batches and, if approved for
use, will also manufacture commercial batches for Celsion&rsquo;s vaccine based on its TheraPlas technology. Poly Pharm is experienced
with chemistry, manufacturing and controls (CMC), process development and good manufacturing processes (cGMP), including process optimization
and manufacturing services to help customers advance new drug development projects. Its sites and pharmaceutical compounds have been
approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), China&rsquo;s National Medical Products
Administration (NMPA) and the World Health Organization (WHO).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><P STYLE="text-align: center; font: 16pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAB 4 &ndash; Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></B></FONT></P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Oral
Presentation on Celsion&rsquo;s Ongoing Work with DNA-based Vaccines at International Vaccines Congress</I></B>. In October 2021, the
Company announced that Khursheed Anwer, Ph.D., executive vice president and chief science officer, presented at the International Vaccines
Congress . Dr. Anwer&rsquo;s presentation was titled &ldquo;Immunogenicity of DNA Vaccines based on Multicistronic Vectors and Synthetic
DNA Delivery Systems&rdquo; and <FONT STYLE="background-color: white">can be viewed <U>here</U>. </FONT>Dr. Anwer discussed ongoing proof-of-concept
studies in SARS-CoV-2 with the Company&rsquo;s DNA-based vaccine approach utilizing its PLACCINE platform. PLACCINE, Celsion&rsquo;s
proprietary design for DNA vectors, encompasses molecular elements designed to improve the immune response by targeting multiple antigens
of a pathogen or multiple mutants of the same antigen. Dr. Anwer also reviewed the PLACCINE technology and the production of a family
of DNA vaccine vectors expressing one or more SARS-CoV-2 surface antigens as a proof-of-concept target, verified vector composition and
demonstrated expression of the encoded genes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Corporate
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Presentations
at Three Healthcare Investment Conferences. </I></B>Celsion management made presentations at the following investment conferences in
October:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chardan&rsquo;s
    5<SUP>th</SUP> Annual Genetic Medicines Conference</I>. Michael H. Tardugno, Celsion&rsquo;s chairman, president and chief executive
    officer, and Khursheed Anwer, Ph.D., Celsion&rsquo;s chief scientific officer, participated in a fireside chat.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>LD
    Micro Main Event</I>. Jeffrey W. Church, Celsion&rsquo;s chief financial officer, presented virtually.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Alliance
    Global Partners&rsquo; Virtual Healthcare Conference</I>. Mr. Tardugno participated in an oncology focused panel discussion moderated
    by James Molloy, Research Analyst.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Third
Quarter Financial Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the quarter ended September 30, 2021, Celsion reported a net loss of $5.4 million ($0.06 per share), compared with a net loss of $8.1
million ($0.24 per share) in the same period of 2020. Operating expenses were $5.2 million in the third quarter of 2021, which represented
a $0.9 million (21%) increase from $4.3 million in the same period of 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company ended the third quarter of 2021 with $60.6 million in cash, investment securities, restricted cash and accrued interest receivable.
Coupled with future sales of unused New Jersey NOL&rsquo;s, the Company believes it has sufficient capital resources to fund its operations
through the end of 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">Research
and development (R&amp;D) expenses were $2.5 million in the third quarter of 2021, consistent with $2.5 million reported in the third
quarter of 2020. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs associated with the OVATION 2
Study were $0.2 million in each of the third quarters of 2021 and 2020. <FONT STYLE="color: windowtext">R&amp;D costs associated with
both the development of GEN-1 to support the OVATION 2 Study and the development of the PLACCINE DNA technology platform increased to
$1.1 million in </FONT>the third quarter of 2021, compared with $0.7 million in the same period of 2020. <FONT STYLE="color: windowtext">Clinical
development costs for the Phase III OPTIMA Study decreased $0.3 million to $0.2 million in the third quarter of 2021, compared with $0.5
million in the third quarter of 2020, due to the discontinuation of this 556-patient trial in the first quarter of 2021. </FONT>Other
costs related to clinical supplies and regulatory support for the Company&rsquo;s clinical development programs decreased to $1.0 million
in the third quarter of 2021 from $1.1 million in the third quarter of 2020, largely driven by higher manufacturing costs for GEN-1 clinical
supplies for the Phase II portion of the OVATION 2 Study, offset by lower regulatory and manufacturing costs related to the OPTIMA Study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><P STYLE="text-align: center; font: 16pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAB 4 &ndash; Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></B></FONT></P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were $2.7 million in the third quarter of 2021, compared with $1.8 million in the same period of 2020. The
$0.9 million increase was primarily attributable to higher non-cash stock-compensation expense ($0.2 million), an increase in legal and
professional fees ($0.6 million) and an increase in Directors&rsquo; and Officers&rsquo; insurance premiums ($0.1 million).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-operating
expenses of $0.3 million in the third quarter of 2021 decreased from $3.9 million in the third quarter of 2020 due to (i) a non-cash
charge of $1.1 million for the change in valuation of the earn-out milestone liability for the GEN-1 ovarian product candidate recognized
in the third quarter of 2020 compared with a $0.3 million non-cash charge recognized in the current quarter; (ii) a n<FONT STYLE="background-color: white">on-cash
charge of $2.4 million related to the impairment of certain in-process research and development assets related to the development of
the Company&rsquo;s glioblastoma multiforme (GBM) cancer product candidate in the third quarter of 2020; and (ii) lower interest expense
of $0.4 million on the Company&rsquo;s debt facilities in the current quarter, compared with the comparable prior year period.</FONT>
In June 2021, the Company entered into a new $10.0 million loan facility with SVB, with a portion of the proceeds used to retire all
outstanding indebtedness under the Company&rsquo;s venture debt facility entered in late June 2018 with Horizon Technology Finance Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nine
Month Financial Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2021, the Company reported a net loss of $16.5 million ($0.21 per share), compared with a net loss
of $18.5 million ($0.62 per share) in the same period of 2020. Operating expenses were $15.9 million during the first nine months of
2021, which represented a $1.8 million (13%) increase from $14.1 million in the same period of 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used for operating activities was $11.1 million in the first nine months of 2021, compared with $11.9 million in the same period
in 2020. This was in line with the Company&rsquo;s projected cash utilization for 2021 of approximately $17 million, or an average of
approximately $4.25 million per quarter. Cash provided by financing activities of $54.8 million during the first nine months of 2021
was derived from equity offerings in January 2021 and April 2021, the $10 million loan facility with SVB in June 2021 and the sale of
the Company&rsquo;s unused New Jersey NOLs in May 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses decreased $0.9 million to $7.6 million in the first nine months of 2021 from $8.5 million in the comparable
prior-year period. Costs associated with the OVATION 2 Study increased to $1.0 million in the first nine months of 2021 compared to $0.7
million in the same period of 2020. The Company initiated enrollment in the Phase 2 portion of the study during the third quarter of
2020. <FONT STYLE="color: windowtext">R&amp;D costs associated with the development of GEN-1 to support the OVATION 2 Study as well as
development of the PLACCINE DNA technology platform</FONT> increased to $3.1 million in the first nine months of 2021, compared with
$2.3 million in the comparable 2020 period. Costs for the Phase III OPTIMA Study decreased $1.2 million to $0.6 million in the first
nine months of 2021, compared with $1.8 million in the first nine months of 2020, <FONT STYLE="color: windowtext">due to the discontinuation
of this trial in the first quarter of 2021. </FONT>Other costs related to clinical supplies and regulatory support for the Company&rsquo;s
clinical development programs decreased $0.8 million to $2.9 million in the first nine months of 2021, compared with the same prior-year
period due to lower regulatory and manufacturing costs for the discontinued Phase III OPTIMA Study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were $8.3 million in the first nine months of 2021, compared with $5.5 million in the same period of 2020.
The $2.8 million increase was primarily attributable to higher non-cash stock-compensation expense ($1.0 million), an increase in legal
and professional fees ($1.4 million) and an increase in Directors&rsquo; and Officers&rsquo; insurance premiums ($0.2 million).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><P STYLE="text-align: center; font: 16pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAB 4 &ndash; Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></B></FONT></P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
expenses during the first nine months of 2021 included a non-cash charge of $0.3 million for the change in valuation of the earn-out
milestone liability for the GEN-1 ovarian product candidate, compared with a non-cash charge of $1.4 million during the comparable prior-year
period and a non-cash <FONT STYLE="background-color: white">charge of $2.4 million related to the impairment of certain in-process research
and development assets related to the development of the Company&rsquo;s GBM cancer product candidate in the third quarter of 2020</FONT>.
In connection with the Company&rsquo;s venture debt facilities, the Company incurred interest expense of $0.5 million during the first
nine months of 2021, compared with $1.1 million during the same period in 2020. In June 2021, the Company entered into a new $10.0 million
loan facility with SVB, with a portion of the proceeds used to retire all outstanding indebtedness under the Company&rsquo;s venture
debt facility with Horizon Technology Finance Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conference
Call</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will host a conference call to provide a business update, discuss its third quarter 2021 financial results and answer questions
at 11:00 a.m. ET today. To participate in the call, please dial 1-800-353-6461(Toll-Free/North America) or +1-334-323-0501 (International/Toll)
and ask for the Celsion Corporation Third Quarter 2021 Earnings Call (Conference Code: 4154518). The call will also be broadcast live
on the internet at <U>www.celsion.com</U>. The call will be archived for replay through December 1, 2021. The replay can be accessed
at +1-719-457-0820 or 888-203-1112 using Conference ID: 4154518. An audio replay will also be available on the Company&rsquo;s website,
<U>www.celsion.com</U>, for 90 days after 2:00 p.m. ET on November 15, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Celsion Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celsion
is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including
immunotherapies and DNA-based therapies, and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV-2.
The company&rsquo;s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion
also has two feasibility-stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anticancer
DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
For more information on Celsion, visit <U>www.celsion.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celsion
GmbH is Celsion&rsquo;s wholly owned, special purpose subsidiary based in Zug, Switzerland. Celsion GmbH is responsible for supporting
studies of ThermoDox<SUP>&reg;</SUP>, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored
development for several cancer indications. For more information on Celsion GmbH, visit <U>www.celsiongmbh.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Celsion
wishes to inform readers that forward-looking statements in this release are made pursuant to the &ldquo;safe harbor&rdquo; provisions
of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and
uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical
trials; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time, and risk of failure
of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other
technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed
from time to time in Celsion&rsquo;s periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes
no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or
otherwise.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Celsion
Investor Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
W. Church</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">609-482-2455<BR>
jchurch@celsion.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LHA
Investor Relations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kim
Sutton Golodetz</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">212-838-3777</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">kgolodetz@lhai.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Tables
to Follow]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><P STYLE="text-align: center; font: 16pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAB 4 &ndash; Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></B></FONT></P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Celsion
Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Condensed
Statements of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in
thousands except per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Three Months Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nine Months Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensing
revenue</B></FONT></P></TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">125</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">125</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">375</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">375</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,468</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,633</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,534</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,719</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,793</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,258</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,533</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,187</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,285</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,891</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,067</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,062</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,160</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(15,516</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(13,692</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">(Loss) from change in valuation of earn-out milestone liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(257</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,100</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(327</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,397</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Impairment of in-process research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,370</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,370</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Loss on debt extinguishment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(235</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Interest expense, investment income and other income (expense), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(92</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(442</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(470</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,012</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total other income (expense), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(349</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,912</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,032</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,779</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,411</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(8,072</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(16,548</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(18,471</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Net loss per common share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.06</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.24</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.21</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.62</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Weighted average shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">86,558</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">34,112</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">79,668</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29,935</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><P STYLE="text-align: center; font: 16pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAB 4 &ndash; Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></B></FONT></P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Celsion
Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selected
Balance Sheet Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in
thousands)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September 30, 2021</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: center"><B>(Unaudited)</B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; width: 60%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">25,649</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">17,164</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Investment securities and interest receivable on investment securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,903</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Advances, deposits on clinical programs and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,213</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,661</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 40pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">56,765</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">18,825</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Property and equipment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">486</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">295</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Deferred tax asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,845</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Restricted cash invested in money market account</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">In-process research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,366</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,366</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt">Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,976</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,976</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Operating lease right-of-use assets, deposits and other assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">876</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,220</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 40pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total other assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">22,218</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">18,407</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><B>Total assets</B></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">79,469</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">37,527</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><B>LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,441</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,703</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Notes payable &ndash; current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,117</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Operating lease liability &ndash; current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">534</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">433</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Deferred revenue - current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 40pt; font-weight: bold; text-align: left">Total current liabilities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">6,475</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">6,753</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Earn-out milestone liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,345</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,018</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Notes payable &ndash; noncurrent portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,809</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,935</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Deferred revenue &ndash; noncurrent portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Operating lease liability &ndash; noncurrent portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">373</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">710</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">20,127</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">18,916</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">866</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">407</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">387,107</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">330,289</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Accumulated other comprehensive gain (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(328,548</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(312,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,696</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Less: Treasury stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(85</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(85</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total stockholders&rsquo; equity</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">59,342</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">18,611</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><B>Total liabilities and stockholders&rsquo; equity</B></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">79,469</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">37,527</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#
# #</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><P STYLE="text-align: center; font: 16pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAB 4 &ndash; Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></B></FONT></P></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo_ex99-1.jpg
<TEXT>
begin 644 logo_ex99-1.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[@ .061O8F4 9      "_]L 0P # @(#
M @(# P,#! ,#! 4(!04$! 4*!P<&" P*# P+"@L+#0X2$ T.$0X+"Q 6$!$3
M%!45%0P/%Q@6%!@2%!44_]L 0P$#! 0%! 4)!04)% T+#104%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  % @
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MF-' Q^V]?)+5OY),\W&8A87#SK/HOQZ?B%%%%>G>&_#\'AO28;.#YL?-(_\
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M'_@!1115_7?".J^'7!O;5EBS@3)\T9_$5AUZAX>^+2R1_9-?MUFB88-Q&O\
MZ$O?\*MZ]\--/URU_M#P]/$I?YA$&S$_T_N_3I7-6X6PN:4I8KARM[5+5TY6
M52/Z2_JS;-(9E4PTE3Q\.6^TE\+_ ,@HHHKR2BK>H:?<:7=26]U T$Z\,CC!
M'^?6JE?FU2G.E-PFK-;IZ-'T,9*2NGH%%%%%%%%9C"BBBBBBB@ HHHHHHHH
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MY=_NZ^9Q?Q6_Y%VW_P"OI?\ T%Z\KKU3XK?\B[;_ /7TO_H+UY77X:_M8?\
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M5_B2]6>[^&_^1=TO_KUB_P#0!6C6=X;_ .1=TO\ Z]8O_0!6C17M?P=NO/\
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M1_PQW\%O^B<:'_WX/^-'_$8,J_Z!JG_DO_R0?V55_F1[-17C/_"PM?\ ^?\
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M_D68;_!#_P!)1\O5_B2]6>[^&_\ D7=+_P"O6+_T 5HUG>&_^1=TO_KUB_\
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M\%/_ /DVN#_L/6O_ *+FK\EZ_6C_ (*?_P#)M<'_ &'K7_T7-7Y+U]!X4_\
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MM.=\S0,9%4XY1N3CN<,3G_>%6?\ A[G_ -4I_P#+C_\ N2C_ (>Y_P#5*?\
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MZ_TG[2TY7)V;<!0?<\\FNAHHK[@_X)0_\EA\7_\ 8"_]N(J_4*OR]_X)0_\
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M;4KH:7X!T[30<3WLK7LJ]<)]U/SQG\*Y&K^J:E+JMX]Q(%3( 1%^[&H& H]
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M N+, 8N(UQMR1PP_A_4=/P^0OVFO^":MW8377B'X2K]LLSF27PU<2_O8N_\
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M:T:/.E%25I*Z"BBBO2I_&EAXS\.W-GJEND>K1QLUM(O1WQQ@]B?2OMGX>_\
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MR\@HHHHHHHK L******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@
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M?5M<M_#.O3+OO/,F.F7$C8R1*&'ER/\ [:Y)_O'%9GC?]L7X0_LV?#F[\'_
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#5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>clsn-20211115.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.7a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaCBibP9z5Z8iekhvWB5bfk6HyoojXPUGCmUkSDWATYI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:CLSN="http://celsion.com/20211115" elementFormDefault="qualified" targetNamespace="http://celsion.com/20211115">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://celsion.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="clsn-20211115_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="clsn-20211115_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>clsn-20211115_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.7a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>clsn-20211115_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.7a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://celsion.com/role/Cover" xlink:href="clsn-20211115.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="clsn-20211115.xsd" xlink:type="simple"/>
    <context id="From2021-11-15to2021-11-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
        </entity>
        <period>
            <startDate>2021-11-15</startDate>
            <endDate>2021-11-15</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-11-15to2021-11-15">0000749647</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-11-15to2021-11-15">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-11-15to2021-11-15">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-11-15to2021-11-15">2021-11-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-11-15to2021-11-15">CELSION CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-11-15to2021-11-15">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-11-15to2021-11-15">001-15911</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-11-15to2021-11-15">52-1256615</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-11-15to2021-11-15">997     Lenox Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-11-15to2021-11-15">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-11-15to2021-11-15">Lawrenceville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-11-15to2021-11-15">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-11-15to2021-11-15">08648-2311</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-11-15to2021-11-15">(609)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-11-15to2021-11-15">896-9100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-11-15to2021-11-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-11-15to2021-11-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-11-15to2021-11-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-11-15to2021-11-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-11-15to2021-11-15">Common     stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-11-15to2021-11-15">CLSN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-11-15to2021-11-15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-11-15to2021-11-15">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140629761373768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 15,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CELSION
CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000749647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-1256615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">997
    Lenox Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lawrenceville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08648-2311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">896-9100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CLSN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( --%;U,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #316]3)&QZU>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)OIVFUA]#-9<63@N""XBTDL[O!I@W)2+MO;QIWNX@^@)!+9OY\
M\PVDTU[H,>!S&#T&LAAO9M</46B_84<B+P"B/J)3L4R)(37W8W"*TC4<P"O]
MH0X(=56UX)"44:1@ 19^)3+9&2UT0$5C...-7O'^,_099C1@CPX'BL!+#DPN
M$_UI[CNX A8887#QNX!F)>;JG]C< 79.SM&NJ6F:RJG)N;0#A[>GQY>\;F&'
M2&K0F%Y%*^CD<<,NDU^;[?WN@<FZJGG!T[G;\4;<MJ)IWQ?7'WY783<:N[?_
MV/@B*#OX]2_D%U!+ P04    " #316]3F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M --%;U-4SF4;3P0  -\0   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9C?<^(V$,>?+W^%ANG#W4R(+8>?-X090LB5'D>X0'LS[?1!V (TL257EH'\
M]UT9L'.I63/E(4C&^_5'N^M=*;V=TB_)AG-#]E$HD[O:QICXL^,D_H9'++E1
M,9?PRTKIB!F8ZK63Q)JS(#.*0L=SW983,2%K_5YV;:;[/96:4$@^TR1)HXCI
MUWL>JMU=C=9.%Y[%>F/L!:??B]F:S[GY/9YIF#FY2B B+A.A)-%\=5<;T,_W
M7M,:9'?\(?@N>3,F=BE+I5[L9!S<U5Q+Q$/N&RO!X&O+ASP,K1)P_',4K>7/
MM(9OQR?UQVSQL)@E2_A0A3]$8#9WM4Z-!'S%TM \J]VO_+B@#-!789+]);O#
MO8U&C?AI8E1T- :"2,C#-]L?'7&)@7<T\#+NPX,RR@=F6+^GU8YH>S>HV4&V
MU,P:X(2T49D;#;\*L#/]H=IRW7,,2-D+CG\TNS^8>6?,IFI[0VCSFGBN1W\V
M=X @Q_!R#"_3N\4PR%^#96(T!.IO1/(VE[S-)!MG)!^4GT+Z&+)XC7G9"G'S
M3OTK M'((1JHR@ (@HSB,63K,@K<?L7"A",<S9RC>9DS9EP+%9"1# CD2ZE?
M<*53Y*\^?*B(?2MG:Z&*(VF$>26/(N1DFD;+\GS$-5R7UFFS2S&>=L[3OH3G
MF:^%S49PVI1%I9["=8:CR7S\-+T:/CW/GIX'"Q@C=)V<KG,)W1""J5E(QC+@
M>_*5OY;QX4HN?-J-;JO11K"Z.5;W$JP%VY-Q &QB)7R6U=WS(<45FUZ=>LU6
MBS81/.H6=<Z]!' L?:5CI3.V:S(W\!(0I<E0I>!0\*L*2D-=H?XPPB#?%&-Z
M">0@"#1/DNO3@$S@/O(DR\EPR6ZW?47@,^%2[<F#AAZ(H18%FWK_'W6Q4Z6H
MN.0\%1 ,ZKH88%'^*5[ WP,.[0PBO5 [60J'RTW83G/I\ZT(0]2#16N@>&U_
M#YCGXDRKK8!'E5+BFM/?,+2B6U"\R+]'FZG$0+'Y4\3G7Q!<T>VT&IVZ=XM6
M:%JT#(K7^RR8 ]B&GN?!!3ZVW.XG#*7H%A0O\Q/E@VMF&R6Q]E4ATNFVZMV*
MS"\Z!,4+^P\MC.$27!-%J3S6X:24"A>JVGW0HCM0O)C/52A\881<DV^0Y5JP
ML)0'5ZGB\8INX.'U>J9YW0?WV#?ZL$F$?1KL0)]6J_+X5>A5DA4MP,/K]7_(
MQDF2 EDE("Y;"?AFIXY7Z84PL%%3*T*]C\M/9,[]%/*M=/]1H63S4\FL.\$Y
MQW^Y)C'39,O"E)-?W!N7DAA6G&R81LF+CN#A)7RA66 S</X:+55I_E4(#"=S
M; OG%:7?P\OTR6EDM/<W3*[YV2UFA=!T,'\8?,>8BIKO753S1Q'7:^NE+Z!@
M-K:(Q$R6AQ<7/)MRSIOCJCWZ?V/VB0D)^0J$W)LVZ.K#:?HP,2K.3K!+9> \
MG TWG,'K8&^ WU=*F=/$'HKS_VGT_P502P,$%     @ TT5O4Y^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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MH'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @
MTT5O4R0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ TT5O4P=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #316]3)&QZ
MU>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " #316]3F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( --%;U-4SF4;3P0  -\0
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " #316]3GZ ;\+$"  #B#   #0              @ &2#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( --%;U.7BKL<P    !,"   +
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4!08     "0 ) #X"  #F$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>clsn-20211115.xsd</File>
    <File>clsn-20211115_lab.xml</File>
    <File>clsn-20211115_pre.xml</File>
    <File>ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "clsn-20211115_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "clsn-20211115_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "clsn-20211115.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "CLSN",
   "nsuri": "http://celsion.com/20211115",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2021-11-15to2021-11-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://celsion.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2021-11-15to2021-11-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://celsion.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001493152-21-028346-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-21-028346-xbrl.zip
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MH_[9"^5**&"43"]D#FWLG8'&WMD+QUZ4C,]G"HEM,3?<'E'W$\YFQ+^2+%@
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M;)_XNK,;W-MIBV_<+_<&5KOE?U!+ P04    " #316]3KFOT<;DX  !)+0(
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MGE- ,?8_L+NN#,6;3YS9KO2DS=U"$/(.<([C1YV"(VZ%J_H]8%-FJUZ?>_>
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M.CYF ("K+NQ0@3]G)2YN3(&9$39Q.C<W$E\3M17P4>)>02 %L-S*6\4P, I
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MWI&;M@H<O8HL/(?.G#40@G+M42% [@;CZ=X;%M^/.;R<L85;N[6<PU^<P]>
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M2L3Z6-,!15R1:T$52YLSZ]G[UEVK,VIV>^EE& M<QL.\H\,&MO6 \R)L+1:
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M,]#]/>HEP^+9'74Q]>+5G:->-LL5+W8NQS'E]I9,/3&;:2%FC<]+"EO@9:*
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M]ZZN T5??8@R^(Y"N=GKNZO;7KYJT?4#K-0([Q+37&,D$Z-:<#$$\Y=M1C@
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M,#(Q,3$Q-5]L86(N>&UL4$L! A0#%     @ TT5O4\+S<F51!P  T5<  !4
M             ( !B X  &-L<VXM,C R,3$Q,35?<')E+GAM;%!+ 0(4 Q0
M   ( --%;U.N:_1QN3@  $DM @ *              "  0P6  !E>#DY+3$N
M:'1M4$L! A0#%     @ TT5O4PK=1W+U$P  P)4   L              ( !
E[4X  &9O<FTX+6LN:'1M4$L%!@     %  4 -@$   MC      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
